FLGT · Fulgent Genetics, Inc.
Market Cap
$540.13M
Shares
27.52M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$322.67M
+13.8%
FY2025
Net Income
-$60.51M
-41.7%
FY2025
Gross Margin
40.56%
+2.7pp
FY2025
Operating Margin
-28.23%
-2.2pp
FY2025
Operating Cash Flow
-$101.64M
-582.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $323.93M | $322.67M | $283.47M | $289.21M | $618.97M | $992.58M | $421.71M | $32.53M | $21.35M | $18.73M | $18.28M | $9.58M | $1.28M | |
| — | — | — | $200K | $300K | $420K | $145K | $0 | — | — | — | — | — | |
| $208.67M | $191.8M | $176.26M | $184.76M | $252.07M | $215.53M | $89.81M | $14.11M | $10.7M | $8.55M | $6.72M | $5.07M | $936K | |
| $115.26M | $130.88M | $107.22M | $104.46M | $366.9M | $777.05M | $331.91M | $18.42M | $10.65M | $10.18M | $11.55M | $4.51M | $342K | |
| — | 40.56% | 37.82% | 36.12% | 59.28% | 78.29% | 78.7% | 56.63% | 49.9% | 54.35% | 63.22% | 47.07% | 26.76% | |
| $56.76M | $53.91M | $48.82M | $41.44M | $28.91M | $24.22M | $11.58M | $6.54M | $5.53M | $4.22M | $3.56M | $4.43M | $521K | |
| $50.07M | $43.37M | $36.25M | $41.47M | $38.92M | $24.44M | $14.95M | $5.9M | $4.65M | $4.21M | $2.47M | $2.67M | $581K | |
| $119.86M | $116.66M | $88.11M | $89M | $111.07M | $50.73M | $15.22M | $6.41M | $5.54M | $5.23M | $4.61M | $2.42M | $230K | |
| $8.69M | $8.03M | $7.97M | $7.85M | $6.5M | $1.71M | — | — | — | — | — | — | — | |
| $25.83M | $24.12M | $24.93M | $26.14M | $32.66M | $11M | $2.96M | $2.11M | — | $1.73M | $1.17M | $575K | $196K | |
| $237.55M | $221.97M | $181.13M | $299.99M | $188.37M | $101.1M | $41.75M | $18.85M | $15.72M | $13.66M | $10.64M | $9.52M | $1.33M | |
| -$122.28M | -$91.1M | -$73.92M | -$195.53M | $178.53M | $675.95M | $290.16M | -$428K | -$5.07M | -$3.48M | $918K | -$5.01M | -$990K | |
| — | -28.23% | -26.08% | -67.61% | 28.84% | 68.1% | 68.8% | -1.32% | -23.75% | -18.59% | 5.02% | -52.34% | -77.46% | |
| -$96.46M | -$66.97M | -$48.99M | -$169.39M | $211.19M | $686.96M | $293.12M | $1.68M | — | -$1.75M | $2.09M | -$4.44M | -$794K | |
| $120K | $75K | -$170K | $488K | $346K | $117K | $20K | — | — | — | — | — | — | |
| $29.87M | $30.92M | $31.3M | $21.61M | $5.62M | — | — | — | — | — | — | — | — | |
| $29.83M | $21.07M | $21.96M | $21.44M | $5.5M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | -$488K | -$777K | -$935K | -$524K | $0 | — | — | |
| -$92.45M | -$70.03M | -$51.96M | -$174.09M | $184.03M | $677.3M | $291.68M | $409K | -$4.64M | -$3M | -$4.47M | -$4.99M | -$990K | |
| -$6.98M | -$8.39M | -$8.14M | $1.15M | $42.1M | $174.8M | $72.53M | $43K | $36K | -$1.02M | $920K | $0 | $0 | |
| -$84.01M | -$60.51M | -$42.71M | -$167.83M | $143.4M | $507.36M | $214.31M | -$411K | -$5.61M | -$2.51M | -$5.35M | -$8.31M | -$4.28M | |
| — | -18.75% | -15.07% | -58.03% | 23.17% | 51.12% | 50.82% | -1.26% | -26.26% | -13.4% | -29.26% | -86.82% | -335.13% | |
| -$1.09M | -$1.12M | -$1.11M | -$7.41M | -$1.48M | -$1.13M | — | — | — | — | — | — | — | |
| -$84.38M | -$60.51M | -$42.71M | -$167.83M | $143.4M | $507.36M | — | — | — | -$2.51M | -$13.67M | — | — | |
| -$88.46M | -$52.63M | -$44.28M | -$145.72M | $123.26M | $506.17M | $214.6M | -$230K | -$5.6M | -$2.45M | -$5.45M | -$8.31M | -$4.28M | |
| shares | — | 30.78M | 30.24M | 29.78M | 30.1M | 29.41M | 22.69M | 18.71M | 17.98M | 17.74M | 13.71M | 11.84M | 0 |
| shares | — | 30.78M | 30.24M | 29.78M | 30.96M | 30.98M | 24.06M | 18.71M | 17.98M | 17.74M | 13.71M | 11.84M | 0 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2025: $110.59M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.89×
EV/EBIT
—
P/E (TTM)
—
Peer median 31.71×
Peer medians compare against the 16 similar-size Diagnostics & Research companies (of 46 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Laboratory Services | $322,224,000 | $283,470,000 | $289,213,000 | $618,968,000 | $992,584,000 |
| Therapeutic Development | $447,000 | $0 | $0 | $0 | $0 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| United States | $296,552,000 | $259,132,000 | $268,977,000 | $603,148,000 | $978,978,000 | $415,334,000 | $25,014,000 |
| Non Us | $26,119,000 | $24,338,000 | $20,236,000 | $15,820,000 | $13,606,000 | $6,378,000 | $7,514,000 |
| Other Countries | $13,213,000 | $11,700,000 | $8,790,000 | $6,881,000 | — | — | — |
| China | $12,906,000 | $12,638,000 | $11,446,000 | $8,939,000 | — | — | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Laboratory Services | -$7,212,000 | -$4,912,000 | -$16,857,000 | $179,343,000 | $675,953,000 |
| Therapeutic Development | -$19,847,000 | -$16,560,000 | -$7,671,000 | -$816,000 | $0 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Laboratory Services | -2.2% | -1.7% | -5.8% | 29% | 68.1% |
| Therapeutic Development | -4440% | — | — | — | — |
Key facts
CIK
1674930
CUSIP
359664109
13F (30d)
124 filings
113 filers
Visit website
Investor relations